Search - tctmd.com

Displaying 41 - 60 of 3138

Sort: Relevancy | Date

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Caitlin E. Cox

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

Todd Neale

October 28, 2025

Presentation TCT 2025

TCT 487: Percutaneous Coronary Intervention with Drug-Coated Balloons in de novo Lesions in Patients with Diabetes Mellitus: A Real-World Experience

Presenter: Victor Alfonso Jimenez Diaz

October 28, 2025

Presentation TCT 2025

Supraflex Cruz versus Xience in Patients with Diabetes and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the TUXEDO-2 Randomized Trial

Presenter: Upendra Kaul

October 28, 2025

Presentation TCT 2025

TCT 498: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors on Cardiovascular Outcomes in Patients with Diabetes Undergoing Percutaneous Coronary Intervention

Presenter: Ahmed A. Mahmoud

October 28, 2025

Presentation TCT 2025

TCT 496: Type 2 Diabetes Is Linked to More Severe Coronary Artery Disease on Cardiac Computed Tomography Angiography but Not to More Invasive Treatment: Insights from a Propensity-Matched Study

Presenter: WIllem Robert van de Vijver

October 28, 2025

Presentation TCT 2025

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

TCT 499: Impact of GLP-1 Agonists on Cardiovascular Outcomes in Obese Adults with HFrEF receiving Guideline Directed Medical Therapy: A Propensity Score Matched Analysis

Presenter: Dawood Shehzad

October 28, 2025

Presentation TCT 2025

TCT 497: Combined Assessment of Lipoprotein(a) and Non-Culprit Coronary LesionSeverity on Clinical Outcomes in Acute Coronary Syndrome

Presenter: Hirokazu Tanaka

October 28, 2025

Presentation TCT 2025

TCT 493: Tailored Antiplatelet Therapy in High-Risk Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention: The Prespecified Analysis of TAILORED-CHIP Trial

Presenter: Seong-Bong Wee

October 28, 2025

Presentation TCT 2025

TCT 489: Socioeconomic Disparities in the Prevalence of Modified Metabolic Syndrome in the United States using National Health and Nutrition Examination Survey 2017–2023 Data

Presenter: Sangho Hyun

October 28, 2025

Presentation TCT 2025

TCT 491: Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled studies

Presenter: Claudio Laudani

October 28, 2025

Presentation TCT 2025

TCT 492: Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiovascular Outcomes Post-PCI in Patients with Diabetes: Findings from the TriNetX Database

Presenter: Aymen Ahmed

October 28, 2025

Presentation TCT 2025

TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

TCT 288: The Diabetes Effect: Mortality Risk Persists in Cardiogenic Shock STEMI Despite Contemporary PCI

Presenter: Miles Chapman

October 27, 2025

Presentation TCT 2025

TCT 1003: Clinical Effectiveness of Glucagon-like peptide-1 receptor agonists on Cardiovascular outcomes Post-PCI in Type 2 Diabetes patients: Findings from the TriNetX Database

Presenter: Aymen Ahmed

October 27, 2025

Presentation TCT 2025

TCT 1283: Clinical Presentation and Long-Term Outcomes of Patients Without Standard Modifiable Cardiovascular Risk Ffactors: Insight from the DECADE Cooperation

Presenter: Claudio Laudani

October 27, 2025

Advertisement

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

What’s Going to Be Hot at AHA 2025?

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

TCT 487: Percutaneous Coronary Intervention with Drug-Coated Balloons in de novo Lesions in Patients with Diabetes Mellitus: A Real-World Experience

Supraflex Cruz versus Xience in Patients with Diabetes and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the TUXEDO-2 Randomized Trial

TCT 498: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors on Cardiovascular Outcomes in Patients with Diabetes Undergoing Percutaneous Coronary Intervention

TCT 496: Type 2 Diabetes Is Linked to More Severe Coronary Artery Disease on Cardiac Computed Tomography Angiography but Not to More Invasive Treatment: Insights from a Propensity-Matched Study

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

TCT 499: Impact of GLP-1 Agonists on Cardiovascular Outcomes in Obese Adults with HFrEF receiving Guideline Directed Medical Therapy: A Propensity Score Matched Analysis

TCT 497: Combined Assessment of Lipoprotein(a) and Non-Culprit Coronary LesionSeverity on Clinical Outcomes in Acute Coronary Syndrome

TCT 493: Tailored Antiplatelet Therapy in High-Risk Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention: The Prespecified Analysis of TAILORED-CHIP Trial

TCT 489: Socioeconomic Disparities in the Prevalence of Modified Metabolic Syndrome in the United States using National Health and Nutrition Examination Survey 2017–2023 Data

TCT 491: Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled studies

TCT 492: Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiovascular Outcomes Post-PCI in Patients with Diabetes: Findings from the TriNetX Database

TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis

TCT 288: The Diabetes Effect: Mortality Risk Persists in Cardiogenic Shock STEMI Despite Contemporary PCI

TCT 1003: Clinical Effectiveness of Glucagon-like peptide-1 receptor agonists on Cardiovascular outcomes Post-PCI in Type 2 Diabetes patients: Findings from the TriNetX Database

TCT 1283: Clinical Presentation and Long-Term Outcomes of Patients Without Standard Modifiable Cardiovascular Risk Ffactors: Insight from the DECADE Cooperation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content